
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is a promising company due to its innovative and unique approach to drug discovery through the Dynamo platform. The company's pipeline of precision medicines, including RLY-8186, RLY-2608, and RLY-4008, has shown promising efficacy in early clinical trials and targets key limitations of existing therapies. Additionally, their partnership with Pfizer for the supply of atirmociclib for their triplet regimen in front-line metastatic breast cancer provides competitive advantage. However, there are inherent risks in drug development and regulatory approval processes, and the company may need to seek additional equity financing to fund their research, potentially diluting shareholder value.
Bears say
Relay Therapeutics is facing potential risks and challenges such as negative clinical data, slower-than-expected development timelines, and competition in the precision medicine market, which could impact their earlier-stage candidates and ultimately lead to lower-than-projected commercial success and potential dilution risk for investors. Furthermore, their reliance on a DCF-based valuation method may not accurately reflect the company's current and future financial performance.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares